Back to top Open menu arrow
Download Reprints
Sections
METHODS RESULTS DISCUSSION LIMITATIONS CONCLUSIONS Article Information Clinical Points
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

Original Research April 29, 2024

Clozapine Use Among People With Psychotic Disorders Who Experience Specific Indications for Clozapine

J Clin Psychiatry 2024;85(2):23m14833

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

Abstract

Objective: To examine rates of clozapine use among people with psychotic disorders who experience specific indications for clozapine.

Methods: Records data from 11 integrated health systems identified patients aged 18 years or older with recorded International Classification of Diseases, Tenth Revision, Clinical Modification, diagnoses of schizophrenia, schizoaffective disorder, or other psychotic disorder who experienced any of the 3 events between January 1, 2019, and December 31, 2019, suggesting indications for clozapine: a diagnosis of self-harm injury or poisoning, suicidal ideation diagnosed or in response to standardized assessments, and hospitalization or emergency department (ED) care for psychotic disorder despite treatment with 2 or more antipsychotic medications. Prescription dispensing data identified all clozapine use prior to or in the 12 months following each indication event. Analyses were conducted with aggregate data from each health system; no individual data were shared.

Results: A total of 7,648 patients with psychotic disorder diagnoses experienced at least 1 indication event. Among 1,097 experiencing a self-harm event, 32 (2.9%) had any prior clozapine use, and 10 (0.9%) initiated clozapine during the following 12 months. Among 6,396 with significant suicidal ideation, 238 (3.7%) had any prior clozapine use, and 70 (1.1%) initiated clozapine over 12 months. Among 881 with hospitalization or ED visit despite pharmacotherapy, 77 (8.7%) had any prior clozapine treatment, and 41 (4.7%) initiated clozapine over 12 months. Among those with significant suicidal ideation, rates of both prior clozapine treatment and subsequent initiation varied significantly by race and ethnicity, with rates among Hispanic and non-Hispanic Black patients lower than among non Hispanic White patients.

Conclusions: Initiating clozapine treatment is uncommon among people with psychotic disorders who experience events suggesting clozapine is indicated, with even lower rates among Black and Hispanic patients.

J Clin Psychiatry 2024;85(2):23m14833

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94–103. PubMed CrossRef
  2. Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:102. PubMed CrossRef
  3. Stroup TS. Clozapine and evidence-based psychopharmacology for schizophrenia. JAMA Psychiatry. 2019;76(10):1007–1008. PubMed CrossRef
  4. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. American Psychiatric Association; 2021.
  5. National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Prevention and Management. National Institute for Health and Care Excellence; 2014.
  6. Remington G, Addington D, Honer W, et al. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604–616. PubMed CrossRef
  7. Forte A, Pompili M, Imbastaro B, et al. Effects on suicidal risk: comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. J Psychopharmacol. 2021;35(9):1074–1080. PubMed CrossRef
  8. Masuda T, Misawa F, Takase M, et al. Association with hospitalization and all cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiatry. 2019;76(10):1052–1062. PubMed CrossRef
  9. Stroup TS, Gerhard T, Crystal S, et al. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry. 2016;173(2):166–173. PubMed CrossRef
  10. Meltzer HY, Alphs L, Green AI, et al; International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91. PubMed CrossRef
  11. Wilkinson ST, Trujillo Diaz D, Rupp ZW, et al. Pharmacological and somatic treatment effects on suicide in adults: a systematic review and meta-analysis. Depress Anxiety. 2022;39(2):100–112. PubMed CrossRef
  12. Zuschlag ZD, Fowler CA, Devendorf A, et al. Clozapine utilization at the United States Veterans Health Administration: a descriptive report of prescribing patterns and patient characteristics among Operation Enduring Freedom/Operation Iraqi Freedom Veterans. Int Clin Psychopharmacol. 2020;35(6):322–328. PubMed CrossRef
  13. Bareis N, Olfson M, Wall M, et al. Variation in psychotropic medication prescription for adults with schizophrenia in the United States. Psychiatr Serv. 2022;73(5):492–500. PubMed CrossRef
  14. Stroup TS, Gerhard T, Crystal S, et al. Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv. 2014;65(2):186–192. PubMed CrossRef
  15. Jones GH, Mitchell BG, Bernard J, et al. History of suicide attempt and clozapine treatment in veterans with schizophrenia or schizoaffective disorder. Prim Care Companion CNS Disord. 2022;24(6):21m03231. PubMed CrossRef
  16. Kelly DL, Freudenreich O, Sayer MA, et al. Addressing barriers to clozapine underutilization: a national effort. Psychiatr Serv. 2018;69(2):224–227. PubMed CrossRef
  17. Farooq S, Choudry A, Cohen D, et al. Barriers to using clozapine in treatment resistant schizophrenia: systematic review. BJPsych Bull. 2019;43(1):8–16. PubMed CrossRef
  18. Verdoux H, Quiles C, Bachmann CJ, et al. Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res. 2018;201:10–19. PubMed CrossRef
  19. Gören JL, Rose AJ, Engle RL, et al. Organizational characteristics of Veterans Affairs clinics with high and low utilization of clozapine. Psychiatr Serv. 2016;67(11):1189–1196. PubMed
  20. Whiskey E, Barnard A, Oloyede E, et al. An evaluation of the variation and underuse of clozapine in the United Kingdom. Acta Psychiatr Scand. 2021;143(4):339–347. PubMed CrossRef
  21. Williams JC, Harowitz J, Glover J, et al. Systematic review of racial disparities in clozapine prescribing. Schizophr Res. 2020;224:11–18. PubMed CrossRef
  22. de Freitas DF, Patel I, Kadra-Scalzo G, et al. Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records. Soc Psychiatr Psychiatr Epidemiol. 2022;57(7):1341–1355. CrossRef
  23. Das-Munshi J, Bhugra D, Crawford MJ. Ethnic minority inequalities in access to treatments for schizophrenia and schizoaffective disorders: findings from a nationally representative cross-sectional study. BMC Med. 2018;16(1):55. PubMed CrossRef
  24. Horvitz-Lennon M, Donohue JM, Lave JR, et al. The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries. Psychiatr Serv. 2013;64(3):230–237. PubMed CrossRef
  25. Manu P, Sarvaiya N, Rogozea LM, et al. Benign ethnic neutropenia and clozapine use: a systematic review of the evidence and treatment recommendations. J Clin Psychiatry. 2016;77(7):e909–e916. PubMed CrossRef
  26. Dotson S, Shtasel D, Freudenreich O. Race–based medicine, clozapine, and benign (ethnic) neutropenia: a call for nuance. Psychiatr Serv. 2021;72(2):232–233. PubMed CrossRef
  27. Coleman KJ, Stewart C, Waitzfelder BE, et al. Racial-ethnic differences in psychiatric diagnoses and treatment across 11 health care systems in the Mental Health Research Network. Psychiatr Serv. 2016;67(7):749–757. PubMed CrossRef
  28. Ross TR, Ng D, Brown JS, et al. The HMO Research Network Virtual Data Warehouse: a public data model to support collaboration. EGEMS (Wash DC). 2014;2(1):1049. PubMed CrossRef
  29. Simon GE, Shortreed SM, Boggs JM, et al. Accuracy of ICD-10-CM encounter diagnoses from health records for identifying self-harm events. J Am Med Inf Assoc. 2022;29(12):2023–2031. CrossRef
  30. Simon GE, Coleman KJ, Rossom RC, et al. Risk of suicide attempt and suicide death following completion of the Patient Health Questionnaire depression module in community practice. J Clin Psychiatry. 2016;77(2):221–227. PubMed CrossRef
  31. Mundt JC, Greist JH, Jefferson JW, et al. Prediction of suicidal behavior in clinical research by lifetime suicidal ideation and behavior ascertained by the electronic Columbia-Suicide Severity Rating Scale. J Clin Psychiatry. 2013;74(9):887–893. PubMed CrossRef
  32. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. PubMed CrossRef
  33. Simon GE, Coleman KJ, Yarborough BJH, et al. First presentation with psychotic symptoms in a population-based sample. Psychiatr Serv. 2017;68(5):456–461. PubMed CrossRef
  34. Schoenbaum M, Sutherland JM, Chappel A, et al. Twelve-month health care use and mortality in commercially insured young people with incident psychosis in the United States. Schizophr Bull. 2017;43(6):1262–1272. PubMed CrossRef
  35. Remington G, Agid O, Foussias G, et al. Clozapine’s role in the treatment of first episode schizophrenia. Am J Psychiatry. 2013;170(2):146–151. PubMed CrossRef
  36. Stokes I, Griffiths SL, Jones R, et al. Prevalence of treatment resistance and clozapine use in early intervention services. BJPsych Open. 2020;6(5):e107. PubMed CrossRef
  37. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–413. CrossRef
  38. Fisher RA. Statistical Methods for Research Workers. Oliver and Boyd; 1954.
  39. Misra S, Etkins OS, Yang LH, et al. Structural racism and inequities in incidence, course of illness, and treatment of psychotic disorders among Black Americans. Am J Public Health. 2022;112(4):624–632. PubMed CrossRef
  40. Givens JL, Houston TK, Van Voorhees BW, et al. Ethnicity and preferences for depression treatment. Gen Hosp Psychiatry. 2007;29(3):182–191. PubMed CrossRef
  41. Tourtellotte R, Lim CT, Battista A. Advancing clozapine use in a community health system. Psychiatr Serv. 2022;73(12):1428. PubMed CrossRef
  42. Carruthers J, Radigan M, Erlich MD, et al. An initiative to improve clozapine prescribing in New York State. Psychiatr Serv. 2016;67(4):369–371. PubMed CrossRef
  43. Simon GE, Yarborough BJ, Rossom RC, et al. Self-reported suicidal ideation as a predictor of suicidal behavior among outpatients with diagnoses of psychotic disorders. Psychiatr Serv. 2019;70(3):176–183. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite